What is Corium?
Corium operates as a specialized biopharmaceutical enterprise dedicated to the advancement and commercialization of neuroscience therapies. The company's core mission centers on providing physicians, patients, and caregivers with innovative treatment options that address significant unmet needs in the central nervous system space. Currently, Corium maintains a robust market presence through the commercialization of two FDA-approved products, ADLARITY and AZSTARYS, within the United States. Beyond domestic operations, the company has strategically licensed these assets for international development, demonstrating a scalable business model that balances domestic commercial execution with global licensing opportunities. Its market position is defined by a rigorous focus on therapeutic efficacy and the operational discipline required to navigate the complexities of the pharmaceutical regulatory environment.
How much funding has Corium raised?
Corium has raised a total of $556M across 2 funding rounds:
Stock Offering
$52M
Private Equity
$504M
Stock Issuance/Offering (2014): $52M, investors not publicly disclosed
Private Equity (2018): $504M led by Gurnet Point Capital
Key Investors in Corium
Gurnet Point Capital
Gurnet Point Capital is a specialized healthcare investment firm that employs a hybrid approach, combining venture capital and private equity strategies to support companies from product development through to commercialization.
Undisclosed Institutional Investor
An undisclosed investor participating in the early-stage capital formation of the company.
Undisclosed Strategic Partner
An undisclosed investor participating in the funding round.
What's next for Corium?
With the recent capital injection, Corium is well-positioned to accelerate its commercialization strategy and deepen its penetration in the neuroscience sector. The company's forward-looking roadmap likely involves the optimization of its supply chain for ADLARITY and AZSTARYS, alongside potential expansion into new geographic territories through its existing licensing framework. As the firm matures, the focus will shift toward sustaining long-term growth through operational excellence and the potential exploration of pipeline assets that complement its current therapeutic offerings. The strategic backing received underscores investor confidence in Corium's ability to execute its commercial mandate while maintaining a high standard of clinical innovation in the neuroscience domain.
See full Corium company page
